|Bid||48.4100 x 800|
|Ask||48.4400 x 1800|
|Day's Range||47.3701 - 48.9600|
|52 Week Range||41.7200 - 99.4500|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.57|
Clovis Oncology, Inc. today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology Annual Meeting taking place June 1-5 in Chicago.
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza. In 1Q18, Merck reported $33 million as its share of the Lynparza alliance revenues, of which $24 million were earned in US markets, while the remaining $9.0 million were reported from international markets. Lynparza is currently the leading PARP inhibitor in terms of new and total prescriptions for its approved label in ovarian cancer and breast cancer indications.
Considered a year ago to be among the top takeover targets in biotech, Tesaro Inc. and Clovis Oncology Inc. have so far failed to live up to their hype on Wall Street. Shares of Tesaro have fallen 71 percent since the U.S. Food and Drug Administration approved its ovarian cancer drug Zejula in March 2017. Clovis is down 32 percent over that time as its competing therapy has also struggled to meet sales estimates.
Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time .
Clovis (CLVS) witnesses wider year-over-year loss in the first quarter. However, the company's revenues beat estimates. Rubraca sales increase.
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catalent, ...
The Boulder, Colorado-based company said it had a loss of $1.54 per share. Losses, adjusted for stock option expense, were $1.30 per share. The results beat Wall Street expectations. The average estimate ...
Clovis Oncology, Inc. reported financial results for the quarter ended March 31, 2018, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for 2018.
Understanding how Clovis Oncology Inc (NASDAQ:CLVS) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense checkRead More...
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Clovis Oncology Inc (NASDAQ:CLVS), with a market cap of US$2.40B, are often out of theRead More...
Clovis Oncology, Inc. will announce its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m.
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Clovis Oncology saw its shares close down over 10% on Monday after announcing that it has commenced two separate underwritten public offerings. Shares of Loxo ...
Clovis Oncology, Inc. announced today the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public of 100% of the principal amount of the notes, before underwriting discounts and commissions.
Clovis Oncology, Inc. announced today that it has commenced two separate underwritten public offerings of convertible senior notes and common stock.
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $130 million.
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
NEW YORK, NY / ACCESSWIRE / April 9, 2018 / U.S. equities experienced weekly losses last week as rising concerns over a potential trade war continued to pressure markets lower on Friday. The Dow Jones ...
The FDA sees promise in speeding the Boulder-based company's drug to a larger range of patients.
Clovis popped midday Friday after the FDA approved another use for its ovarian cancer drug Rubraca — prodding shares of rival Tesaro to topple.
Clovis Oncology, Inc. today announced that the U.S. Food and Drug Administration has approved Rubraca® tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.